Consensus $44.98M. Narrows FY25 adjusted EBITDA loss view to $47M-$51M from $46M-$53M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics options imply 14.6% move in share price post-earnings
- Aquestive appoints Davis as CDO, Slatko as interim CMO, Boyd as CPO
- Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm